BMS-310705 Bristol-Myers Squibb/GBF

Curr Opin Investig Drugs. 2004 Dec;5(12):1292-7.

Abstract

Bristol-Myers Squibb, in collaboration with the German Research Centre for Biotechnology, is developing BMS-310705, an epothilone analog, for the potential treatment of cancer. By April 2002, phase I trials of BMS-310705 were underway.

Publication types

  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents / chemistry
  • Antineoplastic Agents / therapeutic use*
  • Clinical Trials, Phase I as Topic / methods
  • Drugs, Investigational / chemistry
  • Drugs, Investigational / therapeutic use*
  • Epothilones / chemistry
  • Epothilones / therapeutic use*
  • Humans

Substances

  • Antineoplastic Agents
  • BMS 310705
  • Drugs, Investigational
  • Epothilones